TRANSLATIONAL PHYSIOLOGY Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure

Chen, Horng H., Alessandro Cataliotti, John A. Schirger, Fernando L. Martin, and John C. Burnett, Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. Am J Physiol Regul Integr Comp Physiol 288: R1093–R1097, 2005. First published December 30, 2004; doi:10.1152/ajpregu.00682.2004.—A hallmark of overt congestive heart failure (CHF) is attenuated cGMP production by endogenous atrial natriuretic peptide (ANP) with renal resistance to ANP. ANP and brain natriuretic peptides (BNP) are of myocardial origin, whereas urodilatin (Uro) is thought to be derived from kidney. All three peptides are agonists to the natriuretic peptide-A receptor. Our objective was to compare the cardiorenal and humoral actions of ANP, BNP, and Uro in experimental overt CHF. We determined cardiorenal and humoral actions of 90 min of intravenous equimolar infusion of ANP, BNP, and Uro (2 and 10 pmol kg 1 min ) in three separate groups of anesthetized dogs with rapid ventricular pacinginduced overt CHF (240 beats/min for 10 days). BNP resulted in increases in urinary sodium excretion (UNaV) (2.2 0.7 to 164 76 eq/min, P 0.05) and glomerular filtration rate (GFR) (27 4 to 52 11 ml/min, P 0.05) that were greater than those with Uro (P 0.05), whereas ANP did not result in increases in UNaV or GFR. Increases in plasma cGMP (25 2 to 38 2 pmol/ml, P 0.05) and urinary cGMP excretion with BNP (1,618 151 to 6,124 995 pmol/min, P 0.05) were similar to those with Uro; however, there was no change with ANP. Cardiac filling pressures were reduced in all three groups. These studies also support the conclusion that in experimental overt CHF, renal resistance to natriuretic peptides in increasing rank order is BNP Uro ANP.